Botulinum Toxin Injections: 2 Key Factors to Reduce Adverse Outcomes
Every year, more minimally invasive facial aesthetic procedures are carried out all over the globe. The number of nonsurgical injection procedures done in 2017 increased from 2015 by almost 850 000 to over 8.5 million. Botulinum toxin type A (BoNTA) is the most common procedure to be done. Clinical experience with this agent is extensive, and its safety profiles are well characterised. Adverse events (AEs) with BoNTA products are generally transient and mild to moderate in se